Filana Therapeutics, Inc.
FLNA
$0.97
-$0.03-2.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -72.53% | -73.96% | -61.82% | -36.22% | -22.74% |
| Gross Profit | 72.53% | 73.96% | 61.82% | 36.22% | 22.74% |
| SG&A Expenses | -34.04% | -64.78% | -62.67% | -55.99% | -40.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -56.68% | -68.88% | -62.28% | -46.71% | -31.14% |
| Operating Income | 56.68% | 68.88% | 62.28% | 46.71% | 31.14% |
| Income Before Tax | 65.67% | -7.02% | -273.73% | -500.27% | -701.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.67% | -7.02% | -273.73% | -500.27% | -701.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.67% | -7.02% | -273.73% | -500.27% | -701.24% |
| EBIT | 56.68% | 68.88% | 62.28% | 46.71% | 31.14% |
| EBITDA | 57.27% | 69.31% | 62.62% | 46.84% | 31.15% |
| EPS Basic | 65.76% | -6.95% | -327.53% | -505.98% | -553.86% |
| Normalized Basic EPS | 57.61% | 44.68% | -65.54% | -157.13% | -220.20% |
| EPS Diluted | 65.73% | -7.05% | -30.14% | -59.80% | -82.09% |
| Normalized Diluted EPS | 57.61% | 44.68% | -62.39% | -151.57% | -213.33% |
| Average Basic Shares Outstanding | 0.30% | 1.41% | 4.27% | 7.59% | 11.10% |
| Average Diluted Shares Outstanding | 0.30% | 1.41% | 3.65% | 6.93% | 10.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |